AR074528A1 - Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos - Google Patents

Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos

Info

Publication number
AR074528A1
AR074528A1 ARP090103117A ARP090103117A AR074528A1 AR 074528 A1 AR074528 A1 AR 074528A1 AR P090103117 A ARP090103117 A AR P090103117A AR P090103117 A ARP090103117 A AR P090103117A AR 074528 A1 AR074528 A1 AR 074528A1
Authority
AR
Argentina
Prior art keywords
rigid support
plastic
methods
matrix
combinations
Prior art date
Application number
ARP090103117A
Other languages
English (en)
Original Assignee
Duramed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duramed Pharmaceuticals Inc filed Critical Duramed Pharmaceuticals Inc
Publication of AR074528A1 publication Critical patent/AR074528A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Dispositivos intravaginales que tienen un soporte rígido; a métodos para la fabricación de los dispositivos intravaginales; y a sus usos. Los dispositivos comprenden: (a) un soporte rígido que tiene una Dureza Shore A de por lo menos aproximadamente 20 y una resistencia a la tracción de por lo menos aproximadamente 1 MPa; (b) una matriz; y (c) un ingrediente activo disperso en la matriz; donde el soporte y la matriz son adyacentes y donde el dispositivo anular. Reivindicación 5: El dispositivo de la reivindicación 1, donde el soporte comprende un metal, una aleación, un plástico, sus compuestos o sus combinaciones. Reivindicación 6: El dispositivo de la reivindicación 5, donde el plástico comprende un plástico termoplástico o un plástico termoestable. Reivindicación 14: El dispositivo de la reivindicación 1, donde el ingrediente activo es una hormona esteroide, un anticolinérgico, un anestésico, sus combinaciones o derivados. Reivindicación 15: El dispositivo de la reivindicación 1, donde el ingrediente activo es progesterona, estrógeno, oxibutinina, lidocaína, danazol, etonogestrel, etinilestradiol o sus combinaciones. Reivindicación 16: El dispositivo de la reivindicación 1, donde el dispositivo es un anillo vaginal.
ARP090103117A 2008-08-12 2009-08-12 Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos AR074528A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8831408P 2008-08-12 2008-08-12

Publications (1)

Publication Number Publication Date
AR074528A1 true AR074528A1 (es) 2011-01-26

Family

ID=41669143

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103117A AR074528A1 (es) 2008-08-12 2009-08-12 Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos

Country Status (9)

Country Link
US (1) US20100040671A1 (es)
EP (1) EP2320871A4 (es)
JP (1) JP2011530379A (es)
AR (1) AR074528A1 (es)
AU (1) AU2009282496B2 (es)
CA (1) CA2733727A1 (es)
EA (1) EA021371B1 (es)
MX (1) MX338591B (es)
WO (1) WO2010019226A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013000002A (es) * 2001-07-27 2013-04-29 Teva Womens Health Inc Metodos de tratamiento de condiciones patologicas asociadas con vejiga hiperactiva.
JP5695035B2 (ja) 2009-06-03 2015-04-01 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 前眼部薬物供給
SG10201501964QA (en) * 2010-03-16 2015-05-28 Titan Pharmaceuticals Inc Heterogeneous Implantable Devices For Drug Delivery
CA2798034A1 (en) * 2010-03-28 2011-10-13 Evestra, Inc. Intravaginal drug delivery device
CA2798220A1 (en) * 2010-05-05 2011-11-10 Teva Women's Health, Inc. Methods of reducing symptoms in subjects using single dosage forms with tapering release rates
PE20130659A1 (es) * 2010-06-22 2013-06-15 Teva Womens Health Inc Dispositivos intravaginales que comprenden agentes anticolinergicos y metodos para prepararlos
EP2605795A4 (en) * 2010-08-20 2015-06-10 Jiaxiang Tsao INTRAVAGINAL DEVICES AND METHOD FOR THEIR MANUFACTURE AND USE
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
ZA201107786B (en) * 2010-10-26 2012-07-25 Maurice Roger Pope An inhibotor of pathogens
EP2637730B1 (en) * 2010-11-12 2021-08-25 The University of Utah Research Foundation Intravaginal devices for controlled delivery of lubricants
US8926493B2 (en) * 2011-04-11 2015-01-06 The Procter & Gamble Company Pessary device
US20120259165A1 (en) * 2011-04-11 2012-10-11 Nancy Karapasha Lobed pessary device
CN104053449B (zh) * 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
AU2012308317B2 (en) 2011-09-14 2017-01-05 Forsight Vision5, Inc. Ocular insert apparatus and methods
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
TW201332585A (zh) 2012-02-14 2013-08-16 Chemo Res S L 核鞘藥物遞送裝置
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
HUE046128T2 (hu) 2012-10-26 2020-02-28 Forsight Vision5 Inc Szemészeti rendszer gyógyszer szembe való késleltetett kibocsátására
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JPWO2015041353A1 (ja) * 2013-09-20 2017-03-02 潤子 八木 子宮脱又は子宮下垂治療用リングペッサリー
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3017809A1 (en) 2014-11-07 2016-05-11 Ferring B.V. Drug-device unit containing quinagolide
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3018148C (en) 2016-03-23 2024-02-20 The University Of North Carolina At Chapel Hill Geometrically complex intravaginal rings, systems and methods of making the same
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
AR125269A1 (es) * 2021-04-01 2023-06-28 Ceva Sante Animale Composiciones de progesterona de liberación controlada y sus utilizaciones
WO2023031218A1 (en) 2021-08-31 2023-03-09 Ferring B.V. Diagnosis and treatment of ectopic endometriosis

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) * 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
BE791632A (fr) * 1971-11-20 1973-05-21 Schering Ag Supports a base de caoutchouc siliconique pour agents medicamenteux
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4034749A (en) * 1973-12-06 1977-07-12 Schering Aktiengesellschaft Intrauterine contraceptive device
US3993072A (en) * 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
DE2445971A1 (de) * 1974-09-24 1976-04-08 Schering Ag Arzneimittelwirkstofftraeger ii
IL48277A (en) * 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4155991A (en) * 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US4286587A (en) * 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4308867A (en) * 1979-03-23 1982-01-05 Roseman Theodore J Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4402695A (en) * 1980-01-21 1983-09-06 Alza Corporation Device for delivering agent in vagina
DE3040978A1 (de) * 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
NZ200564A (en) * 1982-05-10 1987-03-06 Ahi Operations Ltd Device for slowly releasing chemicals into body cavities of animals
US4961931A (en) * 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
US4629449A (en) * 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
US4553972A (en) * 1983-05-20 1985-11-19 Syntex (U.S.A.) Inc. Disposable intravaginal contraceptive devices releasing 1-substituted imidazoles
NL8302103A (nl) * 1983-06-13 1985-01-02 Fundatech Sa Intravaginaal contraceptisch middel.
US4589880A (en) * 1983-07-14 1986-05-20 Southern Research Institute Disposable spermicide-releasing diaphragm
US4601893A (en) * 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
AU601170B2 (en) * 1985-06-19 1990-09-06 Fortune Capital Management B.V. Pessary
US4827946A (en) * 1988-01-06 1989-05-09 Steven Kaali Electrified vaginal ring
CA2154768A1 (en) * 1993-01-26 1994-08-04 Michael G. Lavean Disposable vaginal device
DE69616551T2 (de) * 1995-07-04 2002-05-29 Akzo Nobel Nv Ringförmige vorrichtung
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
TW358031B (en) * 1997-04-11 1999-05-11 Akze Nobel N V Drug delivery system for 2 or more active substances
US6165166A (en) * 1997-04-25 2000-12-26 Schneider (Usa) Inc. Trilayer, extruded medical tubing and medical devices incorporating such tubing
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
CA2331132C (en) * 1998-05-01 2008-12-16 Fei Enterprises, Ltd. Method for injection molding manufacture of controlled release devices
US6663639B1 (en) * 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US7314716B2 (en) * 1999-11-19 2008-01-01 Mount Sinai School Of Medicine Gustducin γ subunit materials and methods
US6802807B2 (en) * 2001-01-23 2004-10-12 American Medical Systems, Inc. Surgical instrument and method
JP4273208B2 (ja) * 2001-03-30 2009-06-03 チッソ株式会社 婦人科疾患治療剤
AU2002329842B2 (en) * 2001-08-29 2006-09-14 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US7004171B2 (en) * 2002-02-25 2006-02-28 Hi-Gienic Intra Vaginal Technologies Ltd. System for transvaginal drug delivery
DE602004026173D1 (de) * 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
US20060275364A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Flexible Solid Dosage Forms and Methods of Making and Using the Same

Also Published As

Publication number Publication date
CA2733727A1 (en) 2010-02-18
EA021371B1 (ru) 2015-06-30
US20100040671A1 (en) 2010-02-18
AU2009282496A1 (en) 2010-02-18
WO2010019226A1 (en) 2010-02-18
AU2009282496B2 (en) 2015-08-06
EP2320871A4 (en) 2012-09-19
MX2011001605A (es) 2011-05-19
JP2011530379A (ja) 2011-12-22
MX338591B (es) 2016-04-25
EA201170199A1 (ru) 2011-08-30
EP2320871A1 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
AR074528A1 (es) Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos
CR8800A (es) Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona
CL2011003172A1 (es) Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos.
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
ECSP056082A (es) Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
CL2013000423A1 (es) Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2011002209A1 (es) Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
AR039794A1 (es) Formulaciones farmaceuticas de desmopresina
UY33343A (es) Formas de dosificación sólidas orales con dosis muy bajas para la hrt
RS53876B1 (en) PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
DOP2005000248A (es) Agentes citotoxicos que comprendentaxanos nuevos.
CO6251360A2 (es) Bromhidrato de bupropion y aplicaciones terapeuticas
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
PE20181290A1 (es) Formulaciones y metodos para controlar el ciclo reproductivo y la ovulacion
MY179398A (en) Plasticizing mixture for a hydraulic composition
AR038145A1 (es) Composicion de politartrato
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
CO2023000536A2 (es) Formas farmacéuticas de maleato de acalabrutinib
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
PE20130639A1 (es) Metodos de tratamiento de condiciones patologicas asociadas con vejiga hiperactiva
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
CL2012002063A1 (es) Proceso para hacer biodegradable un material polimerico sintetico, que comprende la adicion al material sintetico de una o mas levaduras; equipo para la implementacion de dicho proceso; y uso de levaduras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure